Compare · NVO vs URGN
NVO vs URGN
Side-by-side comparison of Novo Nordisk A/S (NVO) and UroGen Pharma Ltd. (URGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and URGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 140.1x URGN ($1.36B).
- Over the past year, NVO is down 45.0% and URGN is up 296.9% - URGN leads by 341.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 6 for URGN).
- NVO has more recent analyst coverage (25 ratings vs 11 for URGN).
- Company
- Novo Nordisk A/S
- UroGen Pharma Ltd.
- Price
- $43.29+1.17%
- $28.98+3.41%
- Market cap
- $191.15B
- $1.36B
- 1M return
- -7.87%
- -2.70%
- 1Y return
- -45.01%
- +296.92%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 8
- 6
- Recent ratings
- 25
- 11
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
UroGen Pharma Ltd.
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest URGN
- Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $142,561 worth of Ordinary Shares (5,222 units at $27.30), increasing direct ownership by 4% to 139,763 units (SEC Form 4) (for withholding tax)
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma Ltd. filed SEC Form 8-K: Other Events
- UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
- UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Director Robinson James A. Jr. converted options into 2,000 units of ordinary shares, increasing direct ownership by 50% to 6,000 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by UroGen Pharma Ltd.
- UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
- ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
- Chief Medical Officer Schoenberg Mark sold $300,000 worth of Ordinary Shares (10,000 units at $30.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 134,985 units (SEC Form 4)